Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...

Novavax expects 2026 adjusted revenue between $185 million and $205 million, excluding royalties and sales from its licensing ...

Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...

Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

On Thursday, Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million. Higher product sales for the ...

A medical worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax at the Tegel vaccination center on February 28, 2022 in Berlin, Germany. This story was originally published on ...

Novavax (NVAX) officially handed over U.S. marketing rights for its COVID-19 vaccine, Nuvaxovid, to Sanofi. This milestone triggered a $25 million payment to Novavax and highlights progress in their ...

NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is protein ...